CCEL Cryo Cell International (CCEL) Insider Trading, Ownership & Congress Trades
Healthcare Services · Services-misc health & allied services, nec · CIK 0000862692
SEC filings
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
5
13F, latest reported quarter
Conversions, 180 days
1
Codes C/M, not in net · $23.2K priced
CCEL filings, in plain words
Read the full summary
The latest 5% ownership filing is a 13D by Camac Partners, LLC, filed 2026-03-25, for 5.3% of the class. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Cryo Cell International insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
No insider purchases or sales are on record for CRYO CELL INTERNATIONAL INC in the period covered. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 46 earlier Form 4 trades (code P or S) here by this insider (35 buys, 11 sales), the last on Sep 17, 2025.
- -8.7% median (-6.7% mean) 90-day return after 21 previous buys.
- The trade is 1.1% of the 161,833 shares held after it.
- No other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, Co-CEO PORTNOY DAVID bought about $7.9K of CCEL on Sep 18, 2025; 5 funds added in the latest 13F quarter.Context
- 46 earlier Form 4 trades (code P or S) here by this insider (35 buys, 11 sales), the last on Sep 17, 2025.
- -8.7% median (-6.7% mean) 90-day return after 21 previous buys.
- The trade is 0.4% of the 827,344 shares held after it.
- No other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, Co-CEO PORTNOY DAVID bought about $15.2K of CCEL on Sep 18, 2025; 5 funds added in the latest 13F quarter.Context
- 45 earlier Form 4 trades (code P or S) here by this insider (34 buys, 11 sales), the last on Sep 16, 2025.
- -7.9% median (-6.4% mean) 90-day return after 20 previous buys.
- The trade is 0.7% of the 823,933 shares held after it.
- No other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, Co-CEO PORTNOY DAVID bought about $24.6K of CCEL on Sep 17, 2025; 5 funds added in the latest 13F quarter.Context
- 44 earlier Form 4 trades (code P or S) here by this insider (33 buys, 11 sales), the last on Sep 10, 2025.
- -7.1% median (-5.9% mean) 90-day return after 19 previous buys.
- The trade is 0.8% of the 818,369 shares held after it.
- No other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, Co-CEO PORTNOY DAVID bought about $28.8K of CCEL on Sep 16, 2025; 5 funds added in the latest 13F quarter.Context
- 39 earlier Form 4 trades (code P or S) here by this insider (28 buys, 11 sales), the last on Sep 9, 2025.
- -7.9% median (-6.0% mean) 90-day return after 18 previous buys.
- The trade is 4.5% of the 160,082 shares held after it.
- No other insider bought within 30 days.
- 5 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chairman, Co-CEO PORTNOY DAVID bought about $32.3K of CCEL on Sep 10, 2025; 5 funds added in the latest 13F quarter.56 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
no insider buys or sells on file
Congress
no House purchase disclosed in the last 12 months
Funds
5 funds bought in last quarter
below 97% of Healthcare Services
Revenue
-1.3% year over year
below 79% of Healthcare Services
Margin
-7.7% net margin
below 66% of Healthcare Services
Buybacks
$169.5K repurchased, FY to 2025-11-30
below 97% of Healthcare Services
Short interest
0.2% of the float short (float per yahoo 2026-10-26) · 1.0 days to cover · settled 2026-09-30
below 82% of Healthcare Services
What changed in the last 30 days
Nothing new filed in the last 30 days
Watch CCEL
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+12.8%12M
13D/G stake
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns CCEL: institutional holders (13F)
13F holdings, latest reported quarter
165,300 sh
$527.3K
164,976 sh
$526.3K
111,035 sh
$354.2K
46,273 sh
$147.7K
23,346 sh
$74.5K
Congress trades in CCEL
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
13D: intends to influence · 13G: passive
Camac Partners, LLC
Activist 13D · 2026-03-25
5.3%
Camac Capital, LLC
Activist 13D · 2026-03-25
5.3%
Camac Fund, LP
Activist 13D · 2026-03-25
5.3%
Eric Shahinian
Activist 13D · 2026-03-25
5.3%
CCEL planned insider sales (Form 144)
No planned-sale notices
No insider has filed to sell. Watch this after a run-up.
CCEL mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Micro-Cap ETF
$22.0K position · as of 2026-06-30
0.0%
1290 VT Micro Cap Portfolio
$1.7K position · as of 2026-06-30
0.0%
VANGUARD INSTITUTIONAL TOTAL STOCK MARKET INDEX FUND
$88.9K position · as of 2026-06-30
0.0%
Fidelity Extended Market Index Fund
$67.1K position · as of 2026-05-31
0.0%
VANGUARD EXTENDED MARKET INDEX FUND
$144.6K position · as of 2026-06-30
0.0%
Fidelity Total Market Index Fund
$28.8K position · as of 2026-05-31
0.0%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
The complete filing record, in one place.
The record shows 5 funds added last quarter. Each figure is a federal filing, dated the day it went public.
CCEL financials
Revenue growth
-1.3%
XBRL, annual
Net margin
-7.7%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$31.1M
four quarters, 2025-09-01 to 2026-08-31
Revenue, TTM CCEL
| FY Nov 2025 | $31.6M |
| FY Nov 2024 | $32.0M |
| FY Nov 2023 | $31.3M |
| FY Nov 2022 | $30.3M |
| FY Nov 2021 | $28.9M |
| Aug 2026 | $7.8M |
| May 2026 | $7.8M |
| Feb 2026 | $7.7M |
| Nov 2025 | $7.8M |
| Aug 2025 | $7.8M |
| May 2025 | $7.9M |
| Feb 2025 | $8.0M |
| Nov 2024 | $8.0M |
At each fiscal year end
Single quarter
Net margin, TTM
-6.2%
net income over revenue, 2025-09-01 to 2026-08-31
Net margin, TTM CCEL
| FY Nov 2025 | -7.7% |
| FY Nov 2024 | +1.3% |
| FY Nov 2023 | -30.4% |
| FY Nov 2022 | +9.1% |
| FY Nov 2021 | +7.2% |
| Aug 2026 | +16.2% |
| May 2026 | +7.1% |
| Feb 2026 | +0.6% |
| Nov 2025 | -48.7% |
| Aug 2025 | +9.6% |
| May 2025 | +4.5% |
| Feb 2025 | +3.5% |
| Nov 2024 | -23.2% |
At each fiscal year end
Single quarter
Free cash flow, TTM
$4.7M
operating cash flow minus capex, 2025-09-01 to 2026-08-31
Free cash flow, TTM CCEL
| FY Nov 2025 | $5.2M |
| FY Nov 2024 | $3.6M |
| FY Nov 2023 | $2.1M |
| FY Nov 2022 | -$3.6M |
| FY Nov 2021 | $6.1M |
| Aug 2026 | $1.0M |
| May 2026 | $1.8M |
| Feb 2026 | $584.8K |
| Nov 2025 | $1.2M |
| Aug 2025 | $2.5M |
| May 2025 | $644.6K |
| Feb 2025 | $892.0K |
| Nov 2024 | $2.1M |
At each fiscal year end
Single quarter
Debt to equity
n/a
equity is zero or negative, the ratio has no meaning
Debt to equity CCEL
| FY Nov 2025 | n/a |
| FY Nov 2024 | n/a |
| FY Nov 2023 | n/a |
| FY Nov 2022 | n/a |
| FY Nov 2021 | 0.45x |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
0.60x
TTM operating cash flow over long-term debt only, 2026-08-31
Cash flow to debt CCEL
| FY Nov 2025 | 0.66x |
| FY Nov 2024 | 0.71x |
| FY Nov 2023 | 1.04x |
| FY Nov 2022 | 0.98x |
| FY Nov 2021 | 4.18x |
| Aug 2026 | 0.60x |
| May 2026 | 0.76x |
| Feb 2026 | 0.62x |
| Nov 2025 | 0.66x |
| Aug 2025 | 0.76x |
| May 2025 | 0.74x |
| Feb 2025 | 0.87x |
| Nov 2024 | 0.71x |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
n/a
average equity is zero or negative
Return on equity CCEL
| FY Nov 2025 | n/a |
| FY Nov 2024 | n/a |
| FY Nov 2023 | n/a |
| FY Nov 2022 | +208.4% |
| FY Nov 2021 | +274.3% |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-3.1%
TTM net income over average of 2025-08-31 and 2026-08-31
Return on assets CCEL
| FY Nov 2025 | -3.8% |
| FY Nov 2024 | +0.6% |
| FY Nov 2023 | -14.7% |
| FY Nov 2022 | +4.4% |
| FY Nov 2021 | +3.9% |
| Aug 2026 | -3.1% |
| May 2026 | -3.9% |
| Feb 2026 | -4.3% |
| Nov 2025 | -3.8% |
| Aug 2025 | -0.8% |
| May 2025 | -0.3% |
| Feb 2025 | +0.2% |
| Nov 2024 | +0.6% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
pre-tax loss, no effective tax rate to apply
Return on invested capital CCEL
| FY Nov 2025 | n/a |
| FY Nov 2024 | n/a |
| FY Nov 2023 | n/a |
| FY Nov 2022 | +66.2% |
| FY Nov 2021 | n/a |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
+0.4%
operating income (EBIT proxy) over average of 2025-08-31 and 2026-08-31 minus current liabilities
Return on capital employed CCEL
| FY Nov 2025 | +1.1% |
| FY Nov 2024 | +8.0% |
| FY Nov 2023 | -27.6% |
| FY Nov 2022 | +9.5% |
| FY Nov 2021 | +11.6% |
| Aug 2026 | +0.4% |
| May 2026 | -0.2% |
| Feb 2026 | +0.4% |
| Nov 2025 | +1.1% |
| Aug 2025 | +9.6% |
| May 2025 | +8.9% |
| Feb 2025 | +8.7% |
| Nov 2024 | +8.0% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing CCEL
| FY Nov 2025 | n/a |
| FY Nov 2024 | 144.50x |
| FY Nov 2023 | n/a |
| FY Nov 2022 | 13.24x |
| FY Nov 2021 | 51.58x |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | 395.00x |
| Nov 2024 | 144.50x |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
$47.2M
market value at close 2026-10-26 on 2026-10-08 shares, plus long-term debt only, 2026-08-31, minus cash 2026-08-31
Enterprise value CCEL
| FY Nov 2025 | $42.7M |
| FY Nov 2024 | $77.8M |
| FY Nov 2023 | $52.5M |
| FY Nov 2022 | $44.3M |
| FY Nov 2021 | $99.2M |
| Aug 2026 | $40.7M |
| May 2026 | $34.9M |
| Feb 2026 | $35.5M |
| Nov 2025 | $42.7M |
| Aug 2025 | $46.0M |
| May 2025 | $49.7M |
| Feb 2025 | $72.1M |
| Nov 2024 | $77.8M |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
+11.5%
TTM free cash flow over market value at close 2026-10-26
FCF yield CCEL
| FY Nov 2025 | +15.2% |
| FY Nov 2024 | +5.2% |
| FY Nov 2023 | +4.7% |
| FY Nov 2022 | -9.7% |
| FY Nov 2021 | +5.8% |
| Aug 2026 | +13.7% |
| May 2026 | +22.5% |
| Feb 2026 | +18.0% |
| Nov 2025 | +15.2% |
| Aug 2025 | +16.3% |
| May 2025 | +14.3% |
| Feb 2025 | +8.3% |
| Nov 2024 | +5.2% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing CCEL
| FY Nov 2025 | n/a |
| FY Nov 2024 | n/a |
| FY Nov 2023 | n/a |
| FY Nov 2022 | 0.35x |
| FY Nov 2021 | n/a |
| Aug 2026 | n/a |
| May 2026 | n/a |
| Feb 2026 | n/a |
| Nov 2025 | n/a |
| Aug 2025 | n/a |
| May 2025 | n/a |
| Feb 2025 | n/a |
| Nov 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-11 | 2024-11 | 2023-11 | 2022-11 | |
|---|---|---|---|---|
| Revenue | $31.6M | $32.0M | $31.3M | $30.3M |
| Operating income | $482.4K | $3.5M | -$12.3M | $4.0M |
| Net income | -$2.4M | $402.0K | -$9.5M | $2.8M |
| EPS (diluted) | -0.30 | 0.05 | -1.14 | 0.33 |
| Operating cash flow | $5.5M | $6.0M | $8.9M | $8.6M |
| Cash | $319.0K | $561.0K | $406.1K | $1.7M |
| Long-term debt | $8.4M | $8.5M | $8.6M | $8.7M |
| Buybacks | $169.5K | $1.4M | $799.0K | $1.8M |
| Dividends paid | $3.2M | $2.0M | $0 | $7.7M |
SEC XBRL, fiscal years, as known on 2026-10-28
CCEL Stock Sonar score 5/7 axes
Find similar shapesCompareCCEL ranks highest on risk and compliance (93rd percentile) and financial health (78th), and lowest on institutional and government (3rd), among Healthcare Services peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
